Efficacy and safety of abatacept in RA patients in daily clinical practice: An retrospective observational study Orencia as Biological Intensive Treatment for RA

Efficacy and safety of abatacept in RA patients in daily clinical practice: An retrospective observational study Orencia as Biological Intensive Treatment for RA - ORBIT study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008578

Enrollment

100

Registered

2012-08-05

Start date

2012-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who give a full consent to this study 2.Rheumatoid arthritis patinets according to criteria of ACR1987 or ACR/EULAR2010 3.Stable low dose of corticosteroids (<=10mg per day)at least 28 days before enrollment.

Exclusion criteria

Exclusion criteria: Patients who are inadequate by investigator's decision.

Design outcomes

Primary

Measure	Time frame
Proportion of patients with structural remission (modified total Sharp score(mTSS)<=0) at week 24,52,104.	—

Secondary

Measure	Time frame
Proporon (Simplified Disease Activity Index:SDAI<=3.3) or with functional remission (Health Assessment Questionaire:HAQ<=0.5) at week 24, 52,104 Disease Activity Score:DAS28 CRP/SDAI	—

Countries

Japan

Contacts

Public ContactYoshiya Tanaka

University of Occupational and Environmental Health, Japan The First Department of Internal Medicine, School of Medicine

tanaka@med.uoeh-u.ac.jp0936031611

Outcome results